Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55Carcinoma, Non-Small-Cell Lung 33Stomach Neoplasms 28Colorectal Neoplasms 26Small Cell Lung Carcinoma 19Lung Neoplasms 18Rectal Neoplasms 16Pancreatic Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Carcinoma, Hepatocellular 11Recurrence 10Leukemia, Myeloid, Acute 10Melanoma 9Esophageal Squamous Cell Carcinoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Head and Neck Neoplasms 7Hodgkin Disease 6Cholangiocarcinoma 6Adenocarcinoma of Lung 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Germ Cell and Embryonal 5

Interventions

lazertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Lazertinib × Clear all
NCT06156527 2023-12-05

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

National Cancer Center, Korea

Phase 2 Recruiting
120 enrolled

Lazertinib

Data powered by HemOnc (CC BY 4.0) Colophon âš¡